References
- Sandoe JA, Barlow G, Chambers JB, et al. Guidelines for the diagnosis, prevention and management of implantable cardiac electronic device infection. Report of a joint Working Party project on behalf of the British Society for Antimicrobial Chemotherapy (BSAC, host organization), British Heart Rhythm Society (BHRS), British Cardiovascular Society (BCS), British Heart Valve Society (BHVS) and British Society for Echocardiography (BSE). J Antimicrob Chemo 2015;70:325-59
- Sohail MR, Henrikson CA, Braid-Forbes MJ, et al. Mortality and cost associated with cardiovascular implantable electronic device infections. Arch Intern Med 2011;171:1821-8
- Ahsan SY, Saberwal B, Lambiase PD, et al. A simple infection-control protocol to reduce serious cardiac device infections. Europace 2014;16:1482-9
- Greenspon AJ, Patel JD, Lau E, et al. 16-Year Trends in the infection burden for pacemakers and implantable cardioverter-defibrillators in the United States 1993 to 2008. J Am Coll Cardiol 2011;58:6
- Kolek MJ, Patel NJ, Clair WK, et al. Efficacy of a bio-absorbable antibacterial envelope to prevent cardiac implantable electronic device infections in high-risk subjects. J Cardiovasc Electrophysiol 2015;26:1111-16
- Mittal S, Shaw RE, Michel K, et al. Cardiac implantable electronic device infections: incidence, risk factors, and the effect of the AigisRx antibacterial envelope. Heart Rhythm 2014;11:595-601
- Huntingdon Life Sciences Study TR-2013-001, data on file with Medtronic, plc
- World-wide Randomized Antibiotic Envelope Infection Prevention Trial (WRAP-IT): ClinicalTrials.gov 2015 [NCT02277990] https://clinicaltrials.gov/ct2/show/NCT02277990?term=NCT02277990&rank=1
- Perioperative Antibiotic Therapy to Prevent Cardiac Implantable Electronic Device Infections (ENVELOPE): ClinicalTrials.gov 2017 (NCT02809131) [13] https://clinicaltrials.gov/ct2/show/NCT02809131?term=NCT02809131&rank=1
- Bloom HL, Constantin L, Dan D, et al. Implantation success and infection in cardiovascular implantable electronic device procedures utilizing an antibacterial envelope. Pacing Clin Electrophysiol 2011;34:133-42
- Kolek MJ, Dresen WF, Wells QS, et al. Use of an antibacterial envelope is associated with reduced cardiac implantable electronic device infections in high-risk patients. Pacing Clin Electrophysiol 2013;36:354-61
- Shariff N, Eby E, Adelstein E, et al. Health and economic outcomes associated with use of an antimicrobial envelope as a standard of care for cardiac implantable electronic device implantation. J Cardiovasc Electrophysiol 2015;26:783-9
- Henrikson CA, Sohail MR, Acosta H, et al. Antibacterial envelope is associated with low infection rates after implantable cardioverterdefibrillator and cardiac resynchronization therapy device replacement. J Am Coll Cardiol EP 2017;10:1158-1167 http://www.sciencedirect.com/science/article/pii/S2405500X17302505
- Baddour LM, Epstein AE, Erickson CC, et al. Update on cardiovascular implantable electronic device infections and their management: a scientific statement from the American Heart Association. Circulation 2010;121:458-77
- Bongiorni MG, Marinskis G, Lip GY, et al. How European centres diagnose, treat, and prevent CIED infections: results of a European Heart Rhythm Association survey. Europace 2012;14:1666-9
- Sohail MR, Uslan DZ, Khan AH, et al. Infective endocarditis complicating permanent pacemaker and implantable cardioverter-defibrillator infection. Mayo Clin Proc 2008;83:46-53
- National Institute for Health and Care Excellence (NICE). Implantable cardioverter defibrillators for the treatment of arrhythmias and cardiac resynchronisation therapy for the treatment of heart failure (review of TA95 and TA120) Assessment Report. NICE; 2013; https://www.nice.org.uk/guidance/ta314/documents/arrythmias-icds-heart-failure-cardiac-resynchronisation-assessment-report2
- Fleischmann KE, Orav EJ, Lamas GA, et al. Pacemaker implantation and quality of life in the Mode Selection Trial (MOST). Heart Rhythm 2006;3:653-9
- Lopez-Jimenez F, Goldman L, Orav EJ, et al. Health values before and after pacemaker implantation. Am Heart J 2002;144:687-92
- National Institute for Health and Care Excellence (NICE). Implantable cardioverter defibrillators for arrhythmias, TA 95UK. NICE; 2006; https://www.nice.org.uk/guidance/ta95
- National Institute for Health and Care Excellence (NICE). Cardiac resynchronisation therapy for the treatment of heart failure, TA 120UK. NICE: 2007; https://www.nice.org.uk/guidance/ta120
- Claxton K, Martin S, Soares M, et al. Methods for the estimation of the National Institute for Health and Care Excellence cost-effectiveness threshold. Health Technol Assess (Winchester, England) 2015;19:1-503,v–vi